xRead - September 2022

Wise et al.

Page 193

238. Alobid I, Guilemany JM, Mullol J. Nasal manifestations of systemic illnesses. Curr Allergy Asthma Rep. 2004;4:208–216. [PubMed: 15056403] 239. Watts RA, Lane S, Scott DG. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol. 2005;19:191–207. [PubMed: 15857791] 240. Gubbels SP, Barkhuizen A, Hwang PH. Head and neck manifestations of Wegener’s granulomatosis. Otolaryngol Clin North Am. 2003;36:685–705. [PubMed: 14567060] 241. Metaxaris G, Prokopakis EP, Karatzanis AD, et al. Otolaryngologic manifestations of small vessel vasculitis. Auris Nasus Larynx. 2002;29:353–356. [PubMed: 12393040] 242. Diamantopoulos II, Jones NS. The investigation of nasal septal perforations and ulcers. J Laryngol Otol. 2001;115:541–544. [PubMed: 11485583] 243. Grayson PC, Steiling K, Platt M, et al. Defining the nasal transcriptome in granulomatosis with polyangiitis (Wegener’s). Arthritis Rheumatol. 2015;67:2233–2239. [PubMed: 25939343] 244. Izquierdo-Dominguez A, Cordero Castillo A, Alobid I, Mullol J. Churg-Strauss syndrome or eosinophilic granulomatosis with polyangiitis. Sinusitis. 2015;1:24–43. 245. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44. [PubMed: 12840090] 246. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3760–3769. [PubMed: 22729997] 247. Chaigne B, Dion J, Guillevin L, Mouthon L, Terrier B. [Pathophysiology of eosinophilic granulomatosis with polyangitis (Churg-Strauss)]. Rev Med Interne. 2016;37:337–342. French. [PubMed: 26971201] 248. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26:545–553. [PubMed: 25971154] 249. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284–290. [PubMed: 12967693] 250. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet. 2003;361:587–594. [PubMed: 12598156] 251. Gross WL. Churg-Strauss syndrome: update on recent developments. Curr Opin Rheumatol. 2002;14:11–14. [PubMed: 11790990] 252. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336–1343. [PubMed: 20513524] 253. Long CM, Smith TL, Loehrl TA, Komorowski RA, Toohill RJ. Sinonasal disease in patients with sarcoidosis. Am J Rhinol. 2001;15:211–215. [PubMed: 11453511] 254. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J. Sarcoidosis. Lancet. 2014;383:1155–1167. [PubMed: 24090799] 255. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–241. [PubMed: 9012596] 256. Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allergy Immunol. 2015;49:63–78. [PubMed: 25274450] 257. Lawson W, Jiang N, Cheng J. Sinonasal sarcoidosis: a new system of classification acting as a guide to diagnosis and treatment. Am J Rhinol Allergy. 2014;28:317–322. [PubMed: 25197919] 258. Rottoli P, Bargagli E, Chidichimo C, et al. Sarcoidosis with upper respiratory tract involvement. Respir Med. 2006;100:253–257. [PubMed: 15932795] 259. Chapelon-Abric C, Saadoun D, Biard L, et al. Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases. Clin Exp Rheumatol. 2015;33:509–515. [PubMed: 26120779]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.